Characteristics of adults with SCD in the VUMC and UNC cohorts (N = 300)
Patient characteristics . | All patients (N = 300) . | VUMC (n = 150) . | UNC (n = 150) . | P (cohorts)* . | HbSC/HbSβ+ (n = 75) . | HbSS/HbSβ0/HbSD (n = 225) . | P (phenotypes)* . |
---|---|---|---|---|---|---|---|
Age at baseline, median (IQR), y | 28.9 (22.5-40.6) | 25.1 (18.7-31.6) | 35.4 (26.0-43.8) | <.001† | 31.1 (23.7-43.8) | 28.6 (22.0-39.5) | .150† |
Follow-up, mean (SD), y | 6.7 (3.3) | 7.1 (3.7) | 6.3 (2.9) | .045 | 6.6 (3.4) | 6.8 (3.3) | .779 |
Males, % | 43.7 | 48.0 | 39.3 | .130 | 48.0 | 42.2 | .382 |
SCD phenotype (HbSS/HbSβ0/HbSD), % | 75.0 | 68.7 | 81.3 | .011 | NA | NA | NA |
Hemoglobin, mean (SD), g/dL | 9.5 (1.8) | 9.9 (1.8) | 9.2 (1.8) | .001 | 11.2 (1.6) | 9.0 (1.5) | <.001 |
Reticulocyte, mean (SD), % (n = 265) | 8.0 (5.6) | 9.0 (6.5) | 7.2 (4.6) | .009 | 4.2 (3.0) | 9.2 (5.7) | <.001 |
On hydroxyurea, % | 58.7 | 60.0 | 57.3 | .639 | 29.3 | 68.4 | <.001 |
Death, % | 15.3 | 14.7 | 16.0 | .749 | 16.0 | 15.1 | .853 |
Median age of survival for adults with SCD, by starting initial survival age (N = 300) | |||||||
Median (95% CI): survival to ≥18 y | 49.2 (44.4-58.4) (n = 300) | 43.6 (40.6-59.5) (n = 150) | 54.1 (46.3-62.9) (n = 150) | .191‡ | 54.7 (38.6-62.9) | 48.0 (44.4-58.4) | .889‡ |
Median (95% CI): survival to ≥25 y | 54.7 (46.3-60.6) (n = 198) | 54.7 (43.3-60.6) (n = 80) | 54.1 (46.3-62.9) (n = 118) | .858‡ | 56.5 (38.6-62.9) (n = 53) | 51.4 (44.9-59.5) (n = 145) | .926‡ |
Median (95% CI): survival to ≥30 y | 56.5 (46.3-60.6) (n = 138) | 54.7 (40.6-undefined) (n = 42) | 56.5 (46.4-62.9) (n = 96) | .815‡ | 54.7 (38.6-62.9) (n = 38) | 54.1 (46.1-66.1) (n = 100) | .760‡ |
Patient characteristics . | All patients (N = 300) . | VUMC (n = 150) . | UNC (n = 150) . | P (cohorts)* . | HbSC/HbSβ+ (n = 75) . | HbSS/HbSβ0/HbSD (n = 225) . | P (phenotypes)* . |
---|---|---|---|---|---|---|---|
Age at baseline, median (IQR), y | 28.9 (22.5-40.6) | 25.1 (18.7-31.6) | 35.4 (26.0-43.8) | <.001† | 31.1 (23.7-43.8) | 28.6 (22.0-39.5) | .150† |
Follow-up, mean (SD), y | 6.7 (3.3) | 7.1 (3.7) | 6.3 (2.9) | .045 | 6.6 (3.4) | 6.8 (3.3) | .779 |
Males, % | 43.7 | 48.0 | 39.3 | .130 | 48.0 | 42.2 | .382 |
SCD phenotype (HbSS/HbSβ0/HbSD), % | 75.0 | 68.7 | 81.3 | .011 | NA | NA | NA |
Hemoglobin, mean (SD), g/dL | 9.5 (1.8) | 9.9 (1.8) | 9.2 (1.8) | .001 | 11.2 (1.6) | 9.0 (1.5) | <.001 |
Reticulocyte, mean (SD), % (n = 265) | 8.0 (5.6) | 9.0 (6.5) | 7.2 (4.6) | .009 | 4.2 (3.0) | 9.2 (5.7) | <.001 |
On hydroxyurea, % | 58.7 | 60.0 | 57.3 | .639 | 29.3 | 68.4 | <.001 |
Death, % | 15.3 | 14.7 | 16.0 | .749 | 16.0 | 15.1 | .853 |
Median age of survival for adults with SCD, by starting initial survival age (N = 300) | |||||||
Median (95% CI): survival to ≥18 y | 49.2 (44.4-58.4) (n = 300) | 43.6 (40.6-59.5) (n = 150) | 54.1 (46.3-62.9) (n = 150) | .191‡ | 54.7 (38.6-62.9) | 48.0 (44.4-58.4) | .889‡ |
Median (95% CI): survival to ≥25 y | 54.7 (46.3-60.6) (n = 198) | 54.7 (43.3-60.6) (n = 80) | 54.1 (46.3-62.9) (n = 118) | .858‡ | 56.5 (38.6-62.9) (n = 53) | 51.4 (44.9-59.5) (n = 145) | .926‡ |
Median (95% CI): survival to ≥30 y | 56.5 (46.3-60.6) (n = 138) | 54.7 (40.6-undefined) (n = 42) | 56.5 (46.4-62.9) (n = 96) | .815‡ | 54.7 (38.6-62.9) (n = 38) | 54.1 (46.1-66.1) (n = 100) | .760‡ |